<DOC>
	<DOCNO>NCT00006116</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine cisplatin gemcitabine treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy combination cisplatin gemcitabine term response rate progression free survival patient stage IIIB IV non-small cell lung cancer . II . Evaluate treatment regimen term toxicity quality life patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute cisplatin IV 1 hour every 2 week 6 course absence disease progression unacceptable toxicity . Patients disease progression follow 6 course therapy receive additional 6 course therapy . Quality life assess prior course every 3 month . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 37-83 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Locally advance Stage IIIB ( T4 , Nx , M0 , Tx , N3 , M0 ) OR Metastatic disease Stage IV unresectable disease Following cell type eligible : Epidermoid cell Large cell Adenocarcinoma Bidimensionally measurable disease Unresectable recurrence primary surgery allow No brain metastasis PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : AST ALT great 3 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN Renal : Creatinine great 1.10 mg/dL Cardiovascular : No uncontrolled cardiac disease Other : No significant , uncontrolled underlying medical psychiatric condition No serious active infection Neurologically stable No prior malignancy except treat nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics Other : At least 30 day since prior experimental therapy No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2000</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>